Phenotypic Screening with Human iPS Cell–Derived Cardiomyocytes

A major hurdle for cardiovascular disease researchers has been the lack of robust and physiologically relevant cell-based assays for drug discovery. Derivation of cardiomyocytes from human-induced pluripotent stem (iPS) cells at high purity, quality, and quantity enables the development of relevant models of human cardiac disease with source material that meets the demands of high-throughput screening (HTS). Here we demonstrate the utility of iPS cell–derived cardiomyocytes as an in vitro model of cardiac hypertrophy. Exposure of cardiomyocytes to endothelin 1 (ET-1) leads to reactivation of fetal genes, increased cell size, and robust expression of B-type natriuretic peptide (BNP). Using this system, we developed a suite of assays focused on BNP detection, most notably a high-content imaging-based assay designed for phenotypic screening. Miniaturization of this assay to a 384-well format enabled the profiling of a small set of tool compounds known to modulate the hypertrophic response. The assays described here provide consistent and reliable results and have the potential to increase our understanding of the many mechanisms underlying this complex cardiac condition. Moreover, the HTS-compatible workflow allows for the incorporation of human biology into early phases of drug discovery and development.

[1]  D. Rao,et al.  Whole-exome Sequencing and an iPSC-Derived Cardiomyocyte Model Provides a Powerful Platform for Gene Discovery in Left Ventricular Hypertrophy , 2012, Front. Gene..

[2]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[3]  B. Fermini,et al.  Comparative gene expression profiling in human-induced pluripotent stem cell--derived cardiocytes and human and cynomolgus heart tissue. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  Hans Bitter,et al.  Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling. , 2012, Stem cells and development.

[5]  K. Fukunaga,et al.  DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities. , 2009, Cardiovascular therapeutics.

[6]  Y. Hirata,et al.  Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. , 1991, Circulation research.

[7]  S. Pikkarainen,et al.  Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses , 2007, Journal of cellular physiology.

[8]  Julia Gorelik,et al.  Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy? , 2011, Journal of molecular and cellular cardiology.

[9]  J. Moss,et al.  PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4. , 2012, Archives of biochemistry and biophysics.

[10]  R. Willette,et al.  Unrestrained p38 MAPK Activation in Dusp1/4 Double-Null Mice Induces Cardiomyopathy , 2013, Circulation research.

[11]  Michael D. Schneider,et al.  Development of High Content Imaging Methods for Cell Death Detection in Human Pluripotent Stem Cell-Derived Cardiomyocytes , 2012, Journal of Cardiovascular Translational Research.

[12]  J. Hescheler,et al.  Induced Pluripotent Stem Cells: A New Approach for Physiological Research , 2006, Cellular Physiology and Biochemistry.

[13]  J. Januzzi,et al.  Natriuretic peptide testing in heart failure. , 2011, Circulation.

[14]  S. Yamanaka,et al.  Induction of pluripotent stem cells from fibroblast cultures , 2007, Nature Protocols.

[15]  Raffaella Lombardi,et al.  Human Molecular Genetic and Functional Studies Identify TRIM63, Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy , 2012, Circulation research.

[16]  Chunxiang Zhang,et al.  MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. , 2009, Journal of molecular and cellular cardiology.

[17]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[18]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[19]  G. Jennings,et al.  DIFFERENCES BETWEEN PATHOLOGICAL AND PHYSIOLOGICAL CARDIAC HYPERTROPHY: NOVEL THERAPEUTIC STRATEGIES TO TREAT HEART FAILURE , 2007, Clinical and experimental pharmacology & physiology.

[20]  Liang Guo,et al.  Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  D. Kass,et al.  Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface , 2007, Nature Reviews Drug Discovery.

[22]  James A Thomson,et al.  High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.

[23]  K. Kolaja,et al.  Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. , 2011, Toxicology and applied pharmacology.

[24]  ShigetakeSasayama,et al.  Calcineurin Pathway Is Required for Endothelin-1–Mediated Protection Against Oxidant Stress–Induced Apoptosis in Cardiac Myocytes , 2001 .

[25]  R. Stewart,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[26]  A. Clerk,et al.  p90 Ribosomal S6 kinases play a significant role in early gene regulation in the cardiomyocyte response to Gq-protein-coupled receptor stimuli, endothelin-1 and α1-adrenergic receptor agonists , 2012, The Biochemical journal.

[27]  J. Nilsson,et al.  Adrenergic receptor agonists. Benzofuranylethanolamines. , 1980, Journal of medicinal chemistry.

[28]  Kazuwa Nakao,et al.  Transcriptional regulation of the fetal cardiac gene program. , 2012, Journal of pharmacological sciences.

[29]  Yvonne Will,et al.  Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  P. Townsend,et al.  Molecular regulation of cardiac hypertrophy. , 2008, The international journal of biochemistry & cell biology.

[31]  Chad H. Koonce,et al.  Stem Cells and Their Derivatives: A Renaissance in Cardiovascular Translational Research , 2011, Journal of cardiovascular translational research.

[32]  U. Eggert.  The why and how of phenotypic small-molecule screens. , 2013, Nature chemical biology.

[33]  Wolfgang Link,et al.  High content screening: seeing is believing. , 2010, Trends in biotechnology.

[34]  H. Taegtmeyer,et al.  Return to the fetal gene program , 2010, Annals of the New York Academy of Sciences.

[35]  Bruno Becker,et al.  Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. , 2011, Assay and drug development technologies.

[36]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[37]  K. Chien,et al.  Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. , 1990, The Journal of biological chemistry.